Antimicrobial resistance (AMR) is one of the most pressing health challenges facing the world. The situation around AMR is complex, but has led to few public or private resources being used to take on challenges. We propose to solve this challenge by building and innovative platform for technologies. We will do this by collaborating with a number of experts, including peptide chemists, bioinformatics, clinicians and microbiological experts in bacterial toxin-antitoxin systems and infection modeling. This platform will allow us to develop microbial peptides derived from bacterial toxin-antitoxin systems so that they are effective antibiotics that have low toxicity when used in humans and have mechanisms that reduce the development of resistance.
Drug development is more difficult, since it is an unpredictable process. Different areas of expertise are advantageous, as it is the experience of these professionals that together can involve risk and the unpredictability of development. By establishing a consortium of experts, we will combine the complexity associated with the development and design of antibiotics that are effective against antibiotic-resistant infections.
Antimicrobial resistance (AMR) is one of the most pressing challenges facing health service providers. The situation around AMR is complex but has led to relatively few public or private resources being used to tackle the challenge. We propose to address this challenge by building an innovative platform of technologies. We will do this by collaborating with a range of experts including peptide chemists, bioinformaticians, clinicians expert in AMR, and microbiology experts within the fields of bacterial toxin-antitoxin systems and in vitro infection modeling. This platform will allow us to develop lead antimicrobial peptides taken from bacterial toxin-antitoxin systems so that: they are potent, have low human cell line cytotoxicity, have desirable physical properties for ease of delivery, and have modes of action that reduce the rate at which resistance develops.
Drug development is difficult as it is an unpredictable process. Various fields of expertise are advantageous as it is the experience of these professionals that can in aggregate reduce the risks and unpredictabilities of development. By establishing a consortium of experts we will reduce the complexities associated with developing and designing antimicrobials that are effective against antibiotic-resistant infections.